Filing Details
- Accession Number:
- 0001104659-24-099855
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-13 17:08:39
- Reporting Period:
- 2024-09-11
- Accepted Time:
- 2024-09-13 17:08:39
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1442836 | Mersana Therapeutics Inc. | MRSN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1653276 | Jr. H. Martin Huber | C/O Mersana Therapeutics, Inc. 840 Memorial Drive Cambridge MA 02139 | President, Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-09-11 | 166,750 | $0.00 | 166,750 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-09-12 | 50,423 | $1.76 | 116,327 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Disposition | 2024-09-11 | 166,750 | $0.00 | 166,750 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 500,250 | No | 4 | M | Direct |
Footnotes
- Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on September 11, 2023.
- On June 12, 2023, the Reporting Person filed a Form 4 reporting the award of a RSU award representing the right to receive 14,467 shares of common stock of the Issuer on June 8, 2023. Such RSU award was subsequently rescinded in connection with the Reporting Person's appointment as president and chief executive officer effective in September 2023 and as a result was cancelled for no value. The amount of securities beneficially owned reported in this Form 4 reflects an adjustment in the number of shares held by the Reporting Person, reflecting the cancellation of the June 8, 2023 RSU award for no value.
- Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.735 to $1.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- 25% of the RSUs granted vested on September 11, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years.
Billionaire Hedge Funds
